Drug
Faslodex
Faslodex is a pharmaceutical drug with 5 clinical trials. Historical success rate of 50.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
200%(2 trials)
Terminated
1(20%)
Phase Distribution
Ph phase_4
1
20%
Ph phase_1
2
40%
Ph phase_2
2
40%
Phase Distribution
2
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
2(40.0%)
Phase 4Post-market surveillance
1(20.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(1)
Terminated(2)
Other(2)
Detailed Status
unknown2
Terminated1
Withdrawn1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
50.0%
Most Advanced
Phase 4
Trials by Phase
Phase 12 (40.0%)
Phase 22 (40.0%)
Phase 41 (20.0%)
Trials by Status
unknown240%
terminated120%
withdrawn120%
completed120%
Recent Activity
0 active trials
Showing 5 of 5
withdrawnphase_1
Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer
NCT04316169
unknownphase_1
Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer
NCT02626507
terminatedphase_2
Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer
NCT00138125
completedphase_2
Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer
NCT00570323
unknownphase_4
Fulvestrant in Metastatic Breast Cancer
NCT03591549
Clinical Trials (5)
Showing 5 of 5 trials
NCT04316169Phase 1
Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer
NCT02626507Phase 1
Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer
NCT00138125Phase 2
Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer
NCT00570323Phase 2
Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer
NCT03591549Phase 4
Fulvestrant in Metastatic Breast Cancer
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5